Yamaoka, T., Tsurutani, J., Sagara, H., & Ohmori, T. (2020). HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer. Transl Lung Cancer Res.
Styl ChicagoYamaoka, Toshimitsu, Junji Tsurutani, Hironori Sagara, a Tohru Ohmori. "HER2-D16 Oncogenic Driver Mutation Confers Osimertinib Resistance in EGFR Mutation-positive Non-small Cell Lung Cancer." Transl Lung Cancer Res 2020.
Citace podle MLAYamaoka, Toshimitsu, Junji Tsurutani, Hironori Sagara, a Tohru Ohmori. "HER2-D16 Oncogenic Driver Mutation Confers Osimertinib Resistance in EGFR Mutation-positive Non-small Cell Lung Cancer." Transl Lung Cancer Res 2020.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..